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ABSTRACT 
Purpose/Background: The aim of the study is to identify molecular biomarkers involve in 
patients who present with stroke and to determine their clinical usefulness as potential biomarkers 
in stroke patients as compared to patients without stroke. 
Materials & Methods:  All patients presenting with ischemic stroke and hemorrhagic stroke 
at University of New Mexico Hospital (UNMH) will be screened for potential participation in this 
study based on following inclusion and exclusion criteria: 
Inclusion criteria: male/female of ages ≥ 18 years, patients whose standard stroke 
admission order sets are obtained for clinical care. 
Exclusion criteria: Patients <18 year, with the history of prior stroke or any 
neurodegenerative or neuroinflammatory disease except multiple sclerosis (MS), pregnant women 
and prisoners. 
Cytokines will be measured in serum at two different time points: on admission and after 
24 hours of admission. The biomarkers which will measured in serum will include interleukin (IL)-
1, 4, 6, 10, 17, 23, 33, 36, 37, PDGF, VEGFM, TNF-a, ANNULIN, MMP-9, 12, NFk-B, MPO and 
glial factors; GMF, SI000-B and GM-6001. These biomarkers will be evaluated using enzyme 
linked immunosorbent assay (ELISA). Twenty-five percent of the total stroke patient serum 
samples will be matched by controls without ischemic or hemorrhagic stroke. 
The study was approved by UNM institutional review board (IRB). All sample and data 
collection is being done after patient or legally authorized individual sign the informed consent 
form. All the data is being collected on secured RedCAP database.   
Results:   A total of 105 patients will be enrolled during the study period. Two sets of 
samples; one at baseline and the other after 24 hours of admission, will collected from each 
enrolled patient. At present, two patients are enrolled and their samples have been collected and 
stored per study protocol. The study is currently under recruitment phase and it is anticipated that 
the enrollment will be completed within next 2 months. Biomarker analysis will be done 
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sequentially as patients will be enrolled per study protocol. 
Discussion/Conclusion:  The CRISP study will give us understanding about the role of 
various cytokines and/or other biomarkers in the pathogenesis of formation of stroke. These 
biomarkers can potentially serve as identifiers in the clinical surveillance for acute stroke patients. 
The data from this study can be beneficial in the acute management of stroke patients. 
 
